FDA approves Pierre Fabre's paediatric drug Hemangeol to treat infantile hemangioma
The US Food and Drug Administration (FDA) has granted marketing authorisation to Pierre Fabre's paediatric drug Hemangeol (propranolol hydrochloride), as the first and only approved treatment for proliferating infantile hemangioma (IH) requiring syst…
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news
More News: Food and Drug Administration (FDA) | Hemangioma | Inderal | Marketing | Pediatrics | Pharmaceuticals